Verition Fund Management’s Ocular Therapeutix OCUL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.07M Sell
140,000
-159,199
-53% -$1.56M 0.01% 1389
2026
Q2
$2.94M Sell
299,199
-228,139
-43% -$2.07M 0.01% 916
2026
Q1
$4.47M Buy
527,338
+355,732
+207% +$3.39M 0.03% 631
2025
Q4
$2.08M Buy
171,606
+5,573
+3% +$67.7K 0.01% 1580
2025
Q3
$1.94M Buy
166,033
+17,431
+12% +$208K 0.01% 2010
2025
Q2
$1.38M Buy
148,602
+78,172
+111% +$612K 0.01% 2228
2025
Q1
$516K Buy
+70,430
New +$541K ﹤0.01% 2571
2024
Q4
– Sell
-62,501
Closed -$544K – 3434
2024
Q3
$544K Buy
+62,501
New +$515K ﹤0.01% 2268
2023
Q3
– Sell
-54,950
Closed -$284K – 2578
2023
Q2
$284K Buy
+54,950
New +$327K ﹤0.01% 1597
2023
Q1
– Sell
-17,502
Closed -$49.2K – 2443
2022
Q4
$49.2K Buy
17,502
+7,273
+71% +$24.1K ﹤0.01% 1890
2022
Q3
$42K Hold
10,229
– – ﹤0.01% 2705
2022
Q2
$41K Buy
10,229
+229
+2% +$865 ﹤0.01% 2169
2022
Q1
$50K Hold
10,000
– – ﹤0.01% 2489
2021
Q4
$70K Buy
+10,000
New +$77.7K ﹤0.01% 2378

Other funds holding OCUL

Verition Fund Management's OCUL Position: Q3 2026 in Review

Verition Fund Management reduced its Ocular Therapeutix (OCUL) stake by 53% in Q3 2026, selling an estimated $1.56M and leaving 140,000 shares worth $1.07M. The position accounts for 0.01% of the portfolio, ranked #1389.

Verition Fund Management first reported a position in OCUL in Q4 2021 and has held it in 14 quarters since. The position peaked at $4.47M in Q1 2026. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Verition Fund Management held 140,000 shares of Ocular Therapeutix worth $1.07M as of Q3 2026.
  • Verition Fund Management sold 159,199 Ocular Therapeutix shares in Q3 2026, an estimated $1.56M.
  • Ocular Therapeutix made up 0.01% of Verition Fund Management's portfolio in Q3 2026, its #1389 holding.
  • Verition Fund Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 14 quarters since.
  • Verition Fund Management's Ocular Therapeutix position peaked at $4.47M in Q1 2026.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.